skip to main content
Visitante
Meu Espaço
Minha Conta
Sair
Identificação
This feature requires javascript
Tags
Revistas Eletrônicas (eJournals)
Livros Eletrônicos (eBooks)
Bases de Dados
Bibliotecas USP
Ajuda
Ajuda
Idioma:
Inglês
Espanhol
Português
This feature required javascript
This feature requires javascript
Primo Search
Busca Geral
Busca Geral
Acervo Físico
Acervo Físico
Produção Intelectual da USP
Produção USP
Search For:
Clear Search Box
Search in:
Busca Geral
Or hit Enter to replace search target
Or select another collection:
Search in:
Busca Geral
Busca Avançada
Busca por Índices
This feature requires javascript
This feature requires javascript
Cytotoxic drugs and the CD95 pathway
Friesen, C ; Fulda, S ; Debatin, K M
Leukemia, 1999-11, Vol.13 (11), p.1854-1858
[Periódico revisado por pares]
England: Nature Publishing Group
Texto completo disponível
Citações
Citado por
Exibir Online
Detalhes
Resenhas & Tags
Mais Opções
Nº de Citações
This feature requires javascript
Enviar para
Adicionar ao Meu Espaço
Remover do Meu Espaço
E-mail (máximo 30 registros por vez)
Imprimir
Link permanente
Referência
EasyBib
EndNote
RefWorks
del.icio.us
Exportar RIS
Exportar BibTeX
This feature requires javascript
Título:
Cytotoxic drugs and the CD95 pathway
Autor:
Friesen, C
;
Fulda, S
;
Debatin, K M
Assuntos:
Antibodies
;
Antineoplastic Agents - pharmacology
;
Antitumor agents
;
Apoptosis
;
Autocrine signalling
;
CD95 antigen
;
CD95L protein
;
Cell activation
;
Cell death
;
Chemotherapy
;
Cisplatin
;
Cross-resistance
;
Crosslinking
;
Cytarabine
;
Cytotoxicity
;
Doxorubicin
;
Drug resistance
;
Drug Resistance, Neoplasm
;
Drugs
;
Etoposide
;
Fas Ligand Protein
;
fas Receptor - metabolism
;
Humans
;
Leukemia
;
Ligands
;
Membrane Glycoproteins - metabolism
;
Methotrexate
;
Mortality
;
Neoplasms - drug therapy
;
Neoplasms - metabolism
;
Neoplasms - pathology
;
Paracrine signalling
;
Receptors
;
Sensitivity
;
Signal Transduction - drug effects
;
Solid tumors
;
Tumor cells
;
Tumors
É parte de:
Leukemia, 1999-11, Vol.13 (11), p.1854-1858
Notas:
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
Descrição:
Cytotoxic drugs commonly used in chemotherapy of leukemia and solid tumors have been shown to primarily act by inducing apoptosis in sensitive target cells. Apoptosis may involve activation of death-inducing ligand/receptor systems such as CD95 (APO-1/Fas). Treatment with anticancer drugs such as doxorubicin, methotrexate, cytarabine, etoposide and cisplatin at therapeutic concentrations leads to induction of CD95-ligand (CD95-L). CD95-L can mediate cell death in an autocrine/paracrine manner by crosslinking CD95 receptor (CD95). Interfering with CD95-ligand/receptor interaction by antagonistic antibodies to the receptor reduces sensitivity to drug-mediated apoptosis in some cell systems. In addition, treatment with cytotoxic drugs may result in upregulation of CD95, thereby increasing the sensitivity to the CD95 death signal. Apoptosis depends on activation of caspases. Deficient activation of the CD95 system was found in drug-resistant cells. In addition, CD95-resistant and doxorubicin-resistant cells displayed cross-resistance for induction of cell death. Thus, intact apoptosis pathways such as the CD95 system may play a role in determining sensitivity or resistance of tumor cells to chemotherapy.
Editor:
England: Nature Publishing Group
Idioma:
Inglês
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Voltar para lista de resultados
This feature requires javascript
This feature requires javascript
Buscando em bases de dados remotas. Favor aguardar.
Buscando por
em
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento
This feature requires javascript
This feature requires javascript